Table 3.
Summary of cancer characteristics of PSA detected cancers using final clinical pathology (ie, if available after prostatectomy)a.
| Genetic status | BRCA2+ (n = 48) | BRCA2– (n = 15) | p value | BRCA1+ (n = 33) | BRCA1– (n = 20) | p value |
|---|---|---|---|---|---|---|
| Median age (yr) at diagnosis | 61 (56, 64) | 64 (60, 66) | 0.044 | 62 (57, 66) | 61 (58, 62) | 0.3 |
| Median PSA (ng/ml) at diagnosis (IQR) | 4.5 (3.6, 5.5) | 4.2 (3.4, 6.1) | 0.9 | 4.4(3.8, 5.9) | 4.4 (3.6, 5.3) | 0.7 |
| Gleason score 6 | 18 (38) | 11 (73) | 0.019b | 18 (55) | 13 (65) | 0.6a |
| Gleason score 7 (3 + 4) | 15 (31) | 1 (7) | 9 (27) | 4 (20) | ||
| Gleason score 7 (4 + 3) | 9 (19) | 2 (13) | 4 (12) | 3 (15) | ||
| Gleason score 8+ | 6 (12) | 1 (7) | 2 (6) | 0 | ||
| T stage—T1/T2a | 16 (35) | 8 (57) | 0.2b | 9 (31) | 8 (40) | 0.6a |
| T Stage—T2b | 2 (4) | 2 (14) | 0 | 1 (5) | ||
| T Stage—T2c/T3 | 28 (61) | 4 (29) | 20 (69) | 11 (55) | ||
| Risk categoryc—low | 11 (23) | 9 (60) | 0.011b | 10 (30) | 4 (20) | 0.5a |
| Risk categoryc—intermediate | 7 (14.5) | 1 (7) | 3 (9) | 6 (30) | ||
| Risk categoryc—high | 30 (62.5) | 5 (33) | 20 (61) | 10 (50) | ||
| Screening round diagnosed—1 | 25 (52) | 7 (47) | 23 (70) | 13 (65) | ||
| Screening round diagnosed—2 | 7 (14.5) | 1 (7) | 3 (9) | 3 (15) | ||
| Screening round diagnosed—3 | 9 (19) | 5 (33) | 6 (18) | 2 (10) | ||
| Screening round diagnosed—4 | 7 (14.5) | 2 (13) | 1 (3) | 2 (10) | ||
| Active surveillance | 8 (17) | 7 (47) | 5 (17) | 6 (30) | ||
| Radical prostatectomy | 32 (70) | 6 (40) | 22 (76) | 12 (60) | ||
| Nonsurgical treatment | 6 (13) | 2 (13) | 2 (7) | 2 (10) |
IQR = interquartile range; NICE = National Institute for Health and Care Excellence; PSA = prostate-specific antigen.
Some pathology information is not available from sites yet.
Values are presented as median (IQR) and n (%).
a
Note four cancers included in this analysis were diagnosed as a result of additional off-protocol repeat biopsies in men with high PSA.
b
p values calculated on difference between clinically significant disease and non–clinically significant disease.
c
Risk category classification system using NICE guidelines [21].